References
- Wojciechowski P, Lipowska A, Rys P, et al. Impact of FTO genotypes on BMI and weight in polycystic ovary syndrome: a systematic review and meta-analysis. Diabetologia 2012;55:2636–45
- Nandi A, Chen Z, Patel R, Poretsky L. Polycystic ovary syndrome. Endocrinol Metab Clin North Am 2014;43:123–47
- Akinci B. Role of thrombin activatable fibrinolysis inhibitor in endocrine and cardiovascular disorders: an update. Recent Pat Endocr Metab Immune Drug Discov 2012;6:210–17
- Colucci M, Semeraro N. Thrombin activatable fibrinolysis inhibitor: at the nexus of fibrinolysis and inflammation. Thromb Res 2012;129:314–19
- Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996;88:2093–100
- Wang W, Boffa MB, Bajzar L, et al. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998;273:27176–81
- Marx PF. Thrombin-activatable fibrinolysis inhibitor. Curr Med Chem 2004;11:2335–48
- Meltzer ME, Lisman T, de Groot PG, et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010;116:113–21
- Hori Y, Gabazza EC, Yano Y, et al. Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab 2002;87:660–5
- Gumus II, Kargili A, Karakurt F, et al. Levels of thrombin activatable fibrinolysis inhibitor in gestational diabetes mellitus. Gynecol Endocrinol 2013;29:327–30
- Semeraro F, Giordano P, Faienza MF, et al. Evidence that fibrinolytic changes in paediatric obesity translate into a hypofibrinolytic state: relative contribution of TAFI and PAI-1. Thromb Haemost 2012;108:311–17
- Gunes F, Akbal E, Asik M, et al. Number of metabolic syndrome risk parameters associated with TAFIa/ai antigen levels. Blood Coagul Fibrinolysis 2013;24:844–7
- Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41–7
- Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981;140:815–30
- Vonbank A, Saely CH, Rein P, Drexel H. Insulin resistance is significantly associated with the metabolic syndrome, but not with sonographically proven peripheral arterial disease. Cardiovasc Diabetol 2013;12:106 . doi: 10.1186/1475-2840-12-106. Available online at: http://www.ncbi.nlm.nih.gov/pubmed/23866050
- Mak W, Dokras A. Polycystic ovarian syndrome and the risk of cardiovascular disease and thrombosis. Semin Thromb Hemost 2009;35:613–20
- Yildiz BO, Haznedaroğlu IC, Kirazli S, Bayraktar M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J Clin Endocrinol Metab 2002;87:3871–5
- Lindholm A, Bixo M, Eliasson M, et al. Tissue plasminogen activator and plasminogen activator inhibitor 1 in obese and lean patients with polycystic ovary syndrome. Gynecol Endocrinol 2010;26:743–8
- Erdoğan M, Karadeniz M, Alper GE, et al. Thrombin-activatable fibrinolysis inhibitor and cardiovascular risk factors in polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2008;116:143–7
- Oral B, Mermi B, Dilek M, et al. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome. Gynecol Endocrinol 2009;25:110–16
- Karakurt F, Gumus II, Bavbek N, et al. Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome. Gynecol Endocrinol 2008;24:491–7
- Adali E, Yildizhan R, Kurdoglu M, et al. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in young obese women with polycystic ovary syndrome. Fertil Steril 2010;94:666–72